In vivo, the CSF levels of phosphorylated tau in advanced AD patients treated with memantine for 1 year showed a statistically significant reduction, while non-phosphorylated tau and Aβ remained unchanged [38]. This evidence concerns the gene MAPT and Alzheimer disease.